Skip to main content
Equibles
JAZZ logo

JAZZ · Jazz Pharmaceuticals plc · Investor Relations

Track JAZZ — free

Use JAZZ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JAZZ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$241.55 +1.18 (+0.49%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$15.50B
Shares
64.19M
Volume · Nov 13 496.8K Avg daily vol (3M) 874.67K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-17 13:00 UTC Jefferies London Global Healthcare Conference Conference
2026-12-02 13:00 UTC Piper Sandler 38th Annual Healthcare Conference Conference
2026-12-02 20:00 UTC Citi’s 2026 Global Healthcare Conference Conference

Recent news

Date Headline
2026-11-02 Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
2026-09-15 Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
2026-08-31 Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
2026-08-31 Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
2026-08-25 U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
2026-08-10 Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
2026-08-03 Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
2026-05-05 Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
2026-02-24 Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
2025-11-17 Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera ® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
2025-11-05 Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Past events

Date Event Type
2026-11-02 Q3 2026 Jazz Pharmaceuticals Earnings Conference Call Earnings call
2026-09-16 Jazz at Deutsche Bank Healthcare Summit Webcast
2026-09-15 Jazz at Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-10 Jazz at Citi's 2026 Biopharma Back to School Conference Conference
2026-09-09 Jazz at Wells Fargo 21st Annual Healthcare Conference Conference
2026-08-25 Ziihera GEA Investor Webcast Webcast
2026-08-03 Q2 2026 Jazz Pharmaceuticals Earnings Conference Call Earnings call
2026-06-03 2026 Jefferies Healthcare Conference Conference
2026-05-27 TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Event
2026-05-19 2026 RBCCM Global Healthcare Conference Conference
2026-05-05 Q1 2026 Jazz Pharmaceuticals Earnings Conference Call Earnings call
2026-04-15 Needham 25th Annual Healthcare Conference Conference
2026-02-24 Q4 FY2025 Earnings conference call (announced in 8-K) Earnings call
2026-01-13 Jazz at the 44th Annual J.P. Morgan Healthcare Conference Conference
2026-01-09 Zanidatamab HERIZON-GEA-01 Investor Webcast Webcast
2025-08-27 Modeyso Investor Webcast Webcast
2025-08-05 Q2 2025 Jazz Pharmaceuticals Earnings Conference Call Earnings call
2024-03-19 Zanidatamab Virtual R&D Day Webcast

Source: http://investor.jazzpharma.com/investors/events-presentations

Key facts CIK 1232524 CUSIP G50871105 13F (30d) 536 filings 485 filers Visit website Investor relations